All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, KV provides the following cautionary statements identifying important economic, political and technology factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following: (1)
changes in the current and future business environment, including interest
rates and capital and consumer spending; (2) the difficulty of predicting
FDA approvals, including timing, and that any period of exclusivity may not
be realized; (3) acceptance and demand for new pharmaceutical products; (4)
the impact of competitive products and pricing, including as a result of
so-called authorized-generic drugs; (5) new product development and launch,
including the possibility that any product launch may be delayed or that
product acceptance may be less than anticipated; (6) reliance on key
strategic alliances; (7) the availability of raw materials; (8) the
regulatory environment, including regulatory agency and judicial actions
and changes in applicable law or regulations; (9) fluctuations in revenues;
(10) the difficulty of predicting international regulatory approval,
including timing; (11) the difficulty of predicting the pattern of
inventory movements by the Company's customers; (12) the impact of
competitive response to the Company's sales, marketing and strategic
efforts; (13) risks that the Company may not ultimately prevail in
litigation; (14) the proposed restatement of the Company's financial
statements for fiscal periods from 1996 through 2006 and for the quarter
ended June 30, 2006, as well as completion of the Company's financial
statements for the second, third and fourth quarters of fiscal 2007 and for
the full fiscal year
'/>"/>
| SOURCE KV Pharmaceutical Company Copyright©2007 PR Newswire. All rights reserved |